Phase 2
Completed N=227
A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Hyperhidrosis
Source: ClinicalTrials.gov NCT03024255 ↗
Enrolled (actual)
227
Serious AEs
0.4%
Results posted
May 2023
Primary outcomePrimary: Change of Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) Score From Baseline to End of Therapy — -1.30; -2.02; -2.09; -2.10 score on a scale
Summary
This study is being conducted to assess the safety and efficacy of 3 concentrations of BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change of Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) Score From Baseline to End of Therapy |
-1.30; -2.02; -2.09; -2.10 | — |
| PRIMARY Number (%) of Subjects Reporting at Least One Treatment Emergent Adverse Event by Severity |
7; 7; 10; 11; 2; 8 | — |
| SECONDARY Average Gravimetrically Measured Sweat Production (GSP) Observed by Visit, Per Protocol Population |
259.53; 282.41; 281.63; 316.39; 137.36; 124.94 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female subject ≥ 18 years of age.
- Diagnosis of primary axillary hyperhidrosis that meets the following criteria: (a) symptoms of hyperhydrosis for at least 6 months' duration, (b) HDSM-Ax of 3 - 4, (c) HDSS of 3 or 4 and (d) a minimum GSP of 50 mg is each axilla with a combined total of at least 150 mg.
- The ability to understand and follow all study-related procedures including study drug administration.
- Sexually active female of childbearing potential (FOCBP)* must agree to periodic pregnancy testing and use a medically acceptable method of contraception while receiving protocol-assigned product.
Exclusion Criteria
- In the Investigators opinion, any skin or subcutaneous tissue conditions of the axilla(s).
- Prior use of any prohibited medication(s) or procedure(s) within the specified timeframe for the treatment of axillary hyperhidrosis.
- Anticholinergic agents used to treat conditions such as, but not limited to, hyperhidrosis, asthma, incontinence, gastrointestinal cramps, and muscular spasms by any route of administration.
- Use of potent inhibitors of cytochrome P450 CYP3A and CYP2D6.
- Use of any cholinergic drug (e.g. bethanechol) within 30 days.
- Known cause of hyperhidrosis or known history of a condition that may cause hyperhidrosis (i.e., hyperhidrosis secondary to any known cause such hyperthyroidism, diabetes mellitus, medications, etc.).
- Subjects with unstable diabetes mellitus or thyroid disease, history of renal or hepatic impairment, malignancy glaucoma, intestinal obstructive or motility disease, obstructive uropathy, myasthenia gravis, BPH, neurological or psychiatric conditions, Sjögren's or Sicca syndrome, or cardiac abnormalities that may alter or exacerbate sweat production by the use of anticholinergics in the investigator's opinion.
- Subjects with known hypersensitivity to glycopyrrolate, anticholinergics, or any of the components of the topical formulation.
- Subject is pregnant, lactating or is planning to become pregnant during the study.
- History or presence of supraventricular tachycardia, ventricular arrhythmias, atrial fibrillation or atrial flutter.
Data sourced from ClinicalTrials.gov (NCT03024255). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.